DE10311984A8 - Verwendung von NEP-assoziierten Molekülen zur Behandlung von nichtimmunogenen-nichthypertensiven Zivilisationskrankheiten - Google Patents

Verwendung von NEP-assoziierten Molekülen zur Behandlung von nichtimmunogenen-nichthypertensiven Zivilisationskrankheiten Download PDF

Info

Publication number
DE10311984A8
DE10311984A8 DE10311984A DE10311984A DE10311984A8 DE 10311984 A8 DE10311984 A8 DE 10311984A8 DE 10311984 A DE10311984 A DE 10311984A DE 10311984 A DE10311984 A DE 10311984A DE 10311984 A8 DE10311984 A8 DE 10311984A8
Authority
DE
Germany
Prior art keywords
nonimmunogenic
nep
hypertensive
treatment
associated molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE10311984A
Other languages
English (en)
Other versions
DE10311984A1 (de
Inventor
Thomas Dr. Walther
Matthias F. Dr. Melzig
Wolf E. Dr. Siems
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forschungsverbund Berlin FVB eV
Freie Universitaet Berlin
Original Assignee
Forschungsverbund Berlin FVB eV
Freie Universitaet Berlin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forschungsverbund Berlin FVB eV, Freie Universitaet Berlin filed Critical Forschungsverbund Berlin FVB eV
Priority to DE10311984A priority Critical patent/DE10311984A1/de
Priority to EP04718256A priority patent/EP1608355A2/de
Priority to PCT/DE2004/000491 priority patent/WO2004080448A2/de
Publication of DE10311984A1 publication Critical patent/DE10311984A1/de
Publication of DE10311984A8 publication Critical patent/DE10311984A8/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
DE10311984A 2003-03-12 2003-03-12 Verwendung von NEP-assoziierten Molekülen zur Behandlung von nichtimmunogenen-nichthypertensiven Zivilisationskrankheiten Ceased DE10311984A1 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DE10311984A DE10311984A1 (de) 2003-03-12 2003-03-12 Verwendung von NEP-assoziierten Molekülen zur Behandlung von nichtimmunogenen-nichthypertensiven Zivilisationskrankheiten
EP04718256A EP1608355A2 (de) 2003-03-12 2004-03-08 Verwendung von nep-assoziierten molek len zur behandlung von nichtimmunogenen-nichthypertensiven zivilisationskrankheiten
PCT/DE2004/000491 WO2004080448A2 (de) 2003-03-12 2004-03-08 Verwendung von nep-assoziierten molekülen zur behandlung von nichtimmunogenen-nichthypertensiven zivilisationskrankheiten

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10311984A DE10311984A1 (de) 2003-03-12 2003-03-12 Verwendung von NEP-assoziierten Molekülen zur Behandlung von nichtimmunogenen-nichthypertensiven Zivilisationskrankheiten

Publications (2)

Publication Number Publication Date
DE10311984A1 DE10311984A1 (de) 2004-09-23
DE10311984A8 true DE10311984A8 (de) 2005-01-27

Family

ID=32892302

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10311984A Ceased DE10311984A1 (de) 2003-03-12 2003-03-12 Verwendung von NEP-assoziierten Molekülen zur Behandlung von nichtimmunogenen-nichthypertensiven Zivilisationskrankheiten

Country Status (3)

Country Link
EP (1) EP1608355A2 (de)
DE (1) DE10311984A1 (de)
WO (1) WO2004080448A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102499179A (zh) * 2011-11-24 2012-06-20 上海市普陀区中心医院 一种IgAN肾小球硬化大鼠模型的建立方法
WO2018119178A1 (en) * 2016-12-23 2018-06-28 StemBios Technologies, Inc. Use of somatic stem cells for decreasing neprilysin level

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200426A (en) * 1990-08-14 1993-04-06 Board Of Regents, The University Of Texas Inhibitors of neutral endopeptidase/CALLA as chemotherapeutic agents
JPH04112865A (ja) * 1990-09-03 1992-04-14 Dainippon Pharmaceut Co Ltd 置換アミド誘導体
DE4212250A1 (de) * 1992-04-11 1993-10-14 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE69300826T2 (de) * 1993-09-22 1996-04-18 Pfizer Research And Development Co., N.V./S.A., Dublin Hydrierung.
CH690816A5 (de) * 1996-10-24 2001-01-31 Flachsmann Ag Emil Verwendung eines Teil- oder Vollextrates aus nicht fermentierter Camellia sinensis L. zur Herstellung eines Medikamentes, eines Medizinproduktes, eines kosmetischen Präparates oder eines Nahrungsergänzungsproduktes.
EP0977572A1 (de) * 1997-04-24 2000-02-09 Merck Sharp & Dohme Ltd. Verwendung von nk-1 rezeptor-antagonisten zur behandlung von essstörungen
CN1267463A (zh) * 1998-06-08 2000-09-27 扬州四菱食品有限公司 减肥茶及其制作方法
TR200103332T2 (tr) * 1999-05-21 2002-04-22 Pfizer Products Inc. 1-Triflorometil-4-hidroksi-7-piperidinil-aminometilkroman türevleri.
TWI302149B (en) * 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
GB2369118A (en) * 2000-11-17 2002-05-22 Warner Lambert Co Bombesin receptor antagonists
GB0111709D0 (en) * 2001-05-14 2001-07-04 Pfizer Ltd Novel pharmaceuticals
WO2003059289A2 (en) * 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
DE10224844A1 (de) * 2002-06-05 2004-01-08 Solvay Pharmaceuticals Gmbh Nicht-peptidische BRS-3-Agonisten

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
AN 2003:766618 zu: Obese phenotype in NEP knockout mice: Correlation with age and diet and possible molecular mechanism. Becker, M. u.a., NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, (MAR 2003) Vol. 367, Supp. [1], pp. R6-R6. MA 11 [rech. am 17.11.2003] *
CYNSHI, O. u.a.: Antiatherogenic effects of the antioxidant BO-653 in three different animal models. Proc. Natl. Acad. Sci. USA (1998) 95 (17) 10123-10128 *
Datenbank PubMed bei NCBI, Adresse www.ncbi.nlm. *
Datenbank PubMed bei NCBI, Adresse www.ncbi.nlm. nih.gov, Zusammenfassung zu: VALET, P. u.a.: Understanding adipose tissue development from transgenic animal models. J. Lipid Res. (2002) 43 (6) 835-60 [rech. am 18.11.2003]
Datenbank PubMed bei NCBI, Adresse www.ncbi.nlm. nih.gov, Zusammenfassung zu: VALET, P. u.a.: Understanding adipose tissue development from transgenic animal models. J. Lipid Res. (2002) 43 (6) 835-60 [rech. am 18.11.2003] *
Datenbank SCISEARCH bei STN *
Datenbank SCISEARCH bei STN; AN 2003:766618 zu: Obese phenotype in NEP knockout mice: Correlation with age and diet and possible molecular mechanism. Becker, M. u.a., NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, (MAR 2003) Vol. 367, Supp. [1], pp. R6-R6. MA 11 [rech. am 17.11.2003]
IEMS, W.-E. u.a.: Neutral endopeptidase and alcohol consumption, experiments in neutral endopeptidase-deficient mice. Eur. J. Pharmacol. (2000) 397 (2-3) 327-34 *
nih.gov, Zusammenfassung zu: ARBIN, V. u.a.: Acute effect of the dual angiotensin-converting enzyme and neutral endopeptidase 24-11 inhibitor mixanpril on insulin sensitivity in obese Zucker rat. Br. J. Pharmacol. (2001) 133 (4) 495-502 [rech. am 18.11.2003];$
SIEMS, W.-E. u.a.: Neutral endopeptidase and alcohol consumption, experiments in neutral endopeptidase-deficient mice. Eur. J. Pharmacol. (2000) 397 (2-3) 327-34

Also Published As

Publication number Publication date
DE10311984A1 (de) 2004-09-23
WO2004080448A2 (de) 2004-09-23
WO2004080448A3 (de) 2004-12-16
EP1608355A2 (de) 2005-12-28

Similar Documents

Publication Publication Date Title
DE602004022061D1 (de) Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen
ATE518841T1 (de) Herstellung und verwendung von arylalkylsäurederivaten zur behandlung von obesitas
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE494279T1 (de) Zur behandlung von durch crth2 vermittelten krankheiten geeignete pyrimidinderivate
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
ATE524479T1 (de) Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
ATE369133T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE50306850D1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE502005010499D1 (de) Implantat zur Behandlung von Fettsucht
DE60328517D1 (de) Neue verwendung von lycopin zur behandlung von erkrankungen im zusammenhang mit androgenwirkung
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE602006007323D1 (de) VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
ATE423099T1 (de) Zur behandlung von schmerzen geeignete piperazine
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
DE602005015434D1 (de) Mittel zur behandlung von psychoneurotischen krankheiten
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8196 Reprint of faulty title page (publication) german patentblatt: part 1a6
OP8 Request for examination as to paragraph 44 patent law
8181 Inventor (new situation)

Inventor name: MELZIG, MATTHIAS F., DR., 12623 BERLIN, DE

Inventor name: SIEMS, WOLF E., DR., 12683 BERLIN, DE

Inventor name: WALTHER, THOMAS, PROF., 12203 BERLIN, DE

8131 Rejection